Why FDA approval of Agilent Technologies’ Assay is important to cervical cancer patients

The U.S. Food and Drug Administration (FDA) has approved Agilent Technologies’ (NYSE: A) Dako PD-L1 IHC 22C3 pharmDx assay for an expanded use. The expended use is expected to help physicians to identify cervical cancer patients who are most likely to benefit from treatment with Merck’s (MRK) checkpoint inhibitor lmmuno-oncology product Keytruda

PD-L1 IHC 22C3 pharmDx assay was FDA approved for non-small cell lung cancer and subsequently expanded approval for gastric or gastroesophageal junction adenocarcinoma. The current approval makes the assay the first to be approved . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.